JP2024109576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024109576A5 JP2024109576A5 JP2024068916A JP2024068916A JP2024109576A5 JP 2024109576 A5 JP2024109576 A5 JP 2024109576A5 JP 2024068916 A JP2024068916 A JP 2024068916A JP 2024068916 A JP2024068916 A JP 2024068916A JP 2024109576 A5 JP2024109576 A5 JP 2024109576A5
- Authority
- JP
- Japan
- Prior art keywords
- fimh
- polypeptide
- seq
- lectin domain
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 102000004856 Lectins Human genes 0.000 description 9
- 108090001090 Lectins Proteins 0.000 description 9
- 239000002523 lectin Substances 0.000 description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000005583 Pyrin Human genes 0.000 description 1
- 108010059278 Pyrin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000008146 mannosides Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21151126 | 2021-01-12 | ||
| EP21151126.6 | 2021-01-12 | ||
| JP2023541784A JP7532672B2 (ja) | 2021-01-12 | 2022-01-11 | ＦｉｍＨ変異体、それを含む組成物、及びその使用 |
| PCT/IB2022/050166 WO2022153166A1 (en) | 2021-01-12 | 2022-01-11 | Fimh mutants, compositions therewith and use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541784A Division JP7532672B2 (ja) | 2021-01-12 | 2022-01-11 | ＦｉｍＨ変異体、それを含む組成物、及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024109576A JP2024109576A (ja) | 2024-08-14 |
| JP2024109576A5 true JP2024109576A5 (https=) | 2025-01-20 |
Family
ID=74175646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541784A Active JP7532672B2 (ja) | 2021-01-12 | 2022-01-11 | ＦｉｍＨ変異体、それを含む組成物、及びその使用 |
| JP2024068916A Pending JP2024109576A (ja) | 2021-01-12 | 2024-04-22 | ＦｉｍＨ変異体、それを含む組成物、及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541784A Active JP7532672B2 (ja) | 2021-01-12 | 2022-01-11 | ＦｉｍＨ変異体、それを含む組成物、及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11725028B2 (https=) |
| EP (1) | EP4277921A1 (https=) |
| JP (2) | JP7532672B2 (https=) |
| KR (2) | KR20250007029A (https=) |
| CN (1) | CN116888140A (https=) |
| AR (1) | AR124604A1 (https=) |
| AU (1) | AU2022207740B2 (https=) |
| CA (1) | CA3207841A1 (https=) |
| IL (1) | IL303954B2 (https=) |
| MX (1) | MX2023008251A (https=) |
| TW (1) | TW202241929A (https=) |
| WO (1) | WO2022153166A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4461744A3 (en) | 2020-01-16 | 2025-01-08 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| KR20250007029A (ko) | 2021-01-12 | 2025-01-13 | 얀센 파마슈티칼즈, 인코포레이티드 | FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도 |
| PE20241621A1 (es) * | 2021-12-17 | 2024-08-07 | Pfizer | Composiciones de polinucleotidos y sus usos |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JPH0655749B2 (ja) | 1989-09-20 | 1994-07-27 | 日本たばこ産業株式会社 | リピッドａ単糖類縁体 |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| US5593969A (en) | 1991-09-03 | 1997-01-14 | Igen Incorporated | Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| CN1326564C (zh) | 1997-04-01 | 2007-07-18 | 科里克萨有限公司 | 单磷酰基脂质a的水性免疫佐剂组合物 |
| US6500434B1 (en) | 1998-04-23 | 2002-12-31 | Medimmune, Inc. | Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| KR100629028B1 (ko) | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
| EP1194563A1 (en) * | 1999-07-15 | 2002-04-10 | Medimmune, Inc. | Fimh adhesin-based vaccines |
| WO2001025254A2 (en) | 1999-10-04 | 2001-04-12 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
| ES2309064T3 (es) | 2000-04-13 | 2008-12-16 | Corixa Corporation | Composiciones inmunoestimulantes que comprenden un fosfato de aminoalquil glucosaminida y qs-21. |
| AU2001271907A1 (en) | 2000-07-07 | 2002-01-21 | Medimmune, Inc. | FimH adhesin proteins and methods of use |
| WO2002015928A1 (en) | 2000-08-18 | 2002-02-28 | Medimmune, Inc. | METHOD OF ADMINISTERING FimH PROTEIN AS A VACCINE FOR URINARY TRACT INFECTIONS |
| US20030199071A1 (en) | 2000-12-08 | 2003-10-23 | Solomon Langermann | Mutant proteins, high potency inhibitory antibodies and fimch crystal structure |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| CN101019123A (zh) * | 2004-02-06 | 2007-08-15 | 科学与工业研究委员会 | 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法 |
| CN103285392A (zh) | 2005-04-26 | 2013-09-11 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和其用途 |
| ES2353814T3 (es) | 2005-05-11 | 2011-03-07 | Eth Zuerich | Proteinas n-glicosiladas recombinantes de celulas procariotas. |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| CN101983070B (zh) | 2008-02-20 | 2016-03-30 | 格林考瓦因有限公司 | 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物 |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| ES2729967T3 (es) | 2012-02-07 | 2019-11-07 | Infectious Disease Res Inst | Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| US9415101B2 (en) | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9415097B2 (en) | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| WO2015124769A1 (en) | 2014-02-24 | 2015-08-27 | Glycovaxyn Ag | Novel polysaccharide and uses thereof |
| WO2016183501A1 (en) * | 2015-05-13 | 2016-11-17 | University Of Washington | Compositions and methods for treatment and prevention of uropathogenic e. coli infection |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| US11723985B2 (en) * | 2017-09-08 | 2023-08-15 | Cytoseek Limited | Protein delivery to membranes |
| WO2019175147A1 (en) * | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccines against intra-abdominal infections |
| US20240027467A1 (en) * | 2019-12-20 | 2024-01-25 | Vib Vzw | Nanobody Exchange Chromatography |
| EP4461744A3 (en) | 2020-01-16 | 2025-01-08 | Janssen Pharmaceuticals, Inc. | Fimh mutant, compositions therewith and use thereof |
| KR20250007029A (ko) | 2021-01-12 | 2025-01-13 | 얀센 파마슈티칼즈, 인코포레이티드 | FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도 |
-
2022
- 2022-01-11 KR KR1020247041946A patent/KR20250007029A/ko active Pending
- 2022-01-11 MX MX2023008251A patent/MX2023008251A/es unknown
- 2022-01-11 KR KR1020237026809A patent/KR102746713B1/ko active Active
- 2022-01-11 US US17/573,249 patent/US11725028B2/en active Active
- 2022-01-11 EP EP22700099.9A patent/EP4277921A1/en active Pending
- 2022-01-11 CA CA3207841A patent/CA3207841A1/en active Pending
- 2022-01-11 IL IL303954A patent/IL303954B2/en unknown
- 2022-01-11 WO PCT/IB2022/050166 patent/WO2022153166A1/en not_active Ceased
- 2022-01-11 CN CN202280009667.0A patent/CN116888140A/zh active Pending
- 2022-01-11 AR ARP220100049A patent/AR124604A1/es unknown
- 2022-01-11 AU AU2022207740A patent/AU2022207740B2/en active Active
- 2022-01-11 JP JP2023541784A patent/JP7532672B2/ja active Active
- 2022-01-11 TW TW111101159A patent/TW202241929A/zh unknown
-
2023
- 2023-06-26 US US18/341,018 patent/US12297238B2/en active Active
-
2024
- 2024-04-22 JP JP2024068916A patent/JP2024109576A/ja active Pending
-
2025
- 2025-04-08 US US19/173,414 patent/US20250289854A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024109576A5 (https=) | ||
| FI4090363T3 (fi) | FimH-mutantti, sen koostumuksia ja sen käyttö | |
| Bensch et al. | hBD‐1: a novel β‐defensin from human plasma | |
| AU2016289492B2 (en) | Vaccine against RSV | |
| JP2018171063A5 (https=) | ||
| JP2002523517A5 (https=) | ||
| JP2006149365A5 (https=) | ||
| JP2023518596A5 (https=) | ||
| JP2023528207A5 (https=) | ||
| JP6158712B2 (ja) | 新規合成ペプチド及びそれらの使用 | |
| CN113278052B (zh) | 一种重组Protein A蛋白及亲和层析介质的制备方法 | |
| CN105793419A (zh) | 修饰的kz144内溶素序列 | |
| JP2016537979A5 (https=) | ||
| JP2019534884A5 (https=) | ||
| IL303954B2 (en) | FIMH mutants, their compositions and uses | |
| Ryge et al. | Novel lysine‐peptoid hybrids with antibacterial properties | |
| JP2023551122A5 (https=) | ||
| JP2005511038A5 (https=) | ||
| JP2004505640A5 (https=) | ||
| Bromer et al. | The Amino Acid Sequence of Glucagon. II. The Hydrolysis of Glucagon with Chymotrypsin | |
| WO2006046239B1 (en) | A thymus-specific protein | |
| JP2008517998A5 (https=) | ||
| TW200716166A (en) | Lawsonia intracellularis immunological proteins | |
| CN112457378B (zh) | 具有广谱抗菌活性及低溶血性的temporin-1CEc改造肽 | |
| KR102698428B1 (ko) | 유산균 유래 단백질과 대장암 타겟팅 펩타이드를 포함하는 융합 단백질 및 이의 용도 |